Kurth K, Tunn U, Ay R, Schröder F H, Pavone-Macaluso M, Debruyne F, ten Kate F, de Pauw M, Sylvester R
University of Amsterdam, The Netherlands.
J Urol. 1997 Aug;158(2):378-84. doi: 10.1016/s0022-5347(01)64484-7.
We compared the efficacy of transurethral resection alone or transurethral resection followed by bladder instillations of doxorubicin or ethoglucid for 1 year in patients with superficial bladder carcinoma, and followed them long term for the incidence of progression to muscle invasion.
A total of 443 patients with superficial transitional cell carcinoma of the bladder was randomized. After randomization of 206 patients the control arm was closed to patient entry based on the results of an interim analysis showing a significant difference in favor of those receiving adjuvant chemotherapy.
Final analysis of treatment results for recurrence included 432 patients at a median followup of 3.4 years for time to first recurrence, 5 years for analysis of time to invasion (Category T2 disease or worse) and 10.7 years for duration of survival. Time to first recurrence was significantly prolonged by both drugs compared to transurethral resection alone (doxorubicin versus transurethral resection alone p < 0.001 and ethoglucid versus control p < 0.001). Recurrence rate per year was 0.30 for both adjuvant treatment arms and 0.68 for the resection only group. Progression to muscle invasion was rare (15.1% of cases) and not apparently different in the 3 treatment arms. Of the 423 patients death from any cause in 199 and from malignant disease in 59 was not correlated with treatment. However, there was a strong correlation between death from malignant disease, and T category and tumor grade.
In regard to time to first recurrence and recurrence rate per year this study indicates that adjuvant chemotherapy with doxorubicin and ethoglucid using the indicated schedule is superior to transurethral resection alone. However, progression in stage or survival was not influenced by the treatment regimen.
我们比较了单纯经尿道切除术与经尿道切除术后膀胱灌注阿霉素或乙磺半胱氨酸1年对浅表性膀胱癌患者的疗效,并对其进展为肌层浸润的发生率进行了长期随访。
共443例浅表性膀胱移行细胞癌患者被随机分组。在206例患者随机分组后,基于中期分析结果显示接受辅助化疗的患者有显著差异,对照组停止入组。
对复发治疗结果的最终分析包括432例患者,首次复发时间的中位随访时间为3.4年,浸润时间(T2期或更严重分期)分析为5年,生存时间为10.7年。与单纯经尿道切除术相比,两种药物均显著延长了首次复发时间(阿霉素与单纯经尿道切除术相比p<0.001,乙磺半胱氨酸与对照组相比p<0.001)。两个辅助治疗组的年复发率均为0.30,单纯切除术组为0.68。进展为肌层浸润很少见(15.1%的病例),且在三个治疗组中无明显差异。423例患者中,199例死于任何原因,59例死于恶性疾病,与治疗无关。然而,死于恶性疾病与T分期和肿瘤分级之间存在很强的相关性。
就首次复发时间和年复发率而言,本研究表明,按指定方案使用阿霉素和乙磺半胱氨酸进行辅助化疗优于单纯经尿道切除术。然而,治疗方案并未影响分期进展或生存率。